Tempest differentiates through dual-mechanism small molecules designed to activate both tumor killing and immune responses, partnering with pharmaceutical leaders like Roche to de-risk development. The company recently acquired dual-targeting CAR-T programs from Factor Bioscience to expand its pipeline and extend runway while maintaining a capital-efficient strategy with partner-funded programs.
Cyborg Score Rationale
Tempest demonstrates solid fundamentals with a lead program showing clinical activity, strategic partnerships with Roche, recent pipeline expansion through CAR-T acquisition, and analyst support (average rating: Buy with $10.0 price target implying 311% upside). However, clinical-stage risk, cash burn concerns, and pre-revenue status moderate the score.
Top Insights
Lead program Amezalpat advancing in pivotal study with Roche, standard of care regimen in hepatocellular carcinoma with Phase 1b/2 data showing clinical activity
Recently acquired dual-targeting CAR-T programs (Feb 2026) designed to expand portfolio and extend cash runway with partner-funded development approach
Dual mechanism strategy: TPST-1120 (PPAR antagonist) and TPST-1495 (EP2/EP4 antagonist) both advancing Phase 1 trials as monotherapies and in combinations with approved agents
Achieved regulatory approvals including Fast Track and Orphan Drug designations for Amezalpat; China NMPA approval for pivotal trial (June 2025)
Named Competitors
Immuno-oncology small molecules — Traditional checkpoint inhibitors and targeted oncology therapies
CAR-T and cellular immunotherapy — Cell-based cancer therapies competing with Tempest's acquired CAR-T programs
Recent Developments
(February 2026) Announced strategic plan for recently acquired dual-targeting CAR-T assets from Factor Bioscience
(February 2026) Closed acquisition of dual-targeting CAR-T programs
(June 2025) Received China NMPA approval to proceed with pivotal trial for Amezalpat in combination with standard of care
Open the full interactive Tempest Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.